Chromatin and cell aging
1Experimental research; clinical benefit is not established.
What does it do?
KEDA tetrapeptide studied mainly in ex-vivo lymphocytes and rat tissue, with concentrated research networks. Clinical liver protection or anti-aging efficacy is unestablished.
Approved & studied uses
Community uses Reported, unvalidated
Cellular aging and liver biology
12Ex-vivo chromatin and cultured-hepatocyte protein-synthesis findings.
Inflammation/opioid biology
12In-vitro enzyme inhibition only.
Liver/digestive recovery
12Animal hepatitis/cirrhosis and oral digestive-enzyme research.
Immune-cell protection
12Chromosomal protection outside the body, not clinical immunity.
Reasons people report using it; these do not establish benefit.12
Evidence limits
View research →Clinical liver benefits, human pharmacokinetics and treatment safety were not established.1
1 distinct primary sources or abstracts checked. Evidence may concern a parent compound, individual blend ingredient, animal, or cell model; it does not necessarily establish a benefit for this exact product.
Evidence definitions →Key safety information
All risks →Clinical gap
Cell-culture chromatin changes do not establish liver regeneration or clinical anti-aging safety.1
Investigational; this profile does not establish an approved use.
Amino-acid sequence
- Lys
- Glu
- Asp
- Ala
4 residues · N → C1
Reference identity · not independently confirmed12
Length4 amino acids
Molecular weight · Da461.5 Da
Formula, sequence notation & identity
K–E–D–ALys–Glu–Asp–Ala (KEDA)
Sequence and formulation must be confirmed for the exact material; similarly named products are not necessarily interchangeable.
Pep-Pedia identity details
4 amino acids (tetrapeptide) · 461.5 Da
Lys-Glu-Asp-Ala (H-K-E-D-A-OH)Reference description; checked chemical identity above takes precedence when available.12
Pharmacokinetics
How long does it stay in the body?
Unverified reference estimateNot independently confirmed
Reference half-life30 min11
Route / formulationSource page: Injectable. Exact PK route not verified.
This value is reported by a secondary reference. The stated attribution has not been independently verified as a route- and formulation-matched human PK measurement.
50%of reference level
Illustrative scenario using an unverified reference estimate.
About 3% remaining after 2.5 h
Five half-lives in this estimated model. This is not a prediction of when effects stop.
Evidence and model details
Population: Not established by the reference estimate
Source’s stated attribution: Timofeeva et al. 2005 Adv Gerontol (PMID 16075683)
Source’s reported peak time: 3 min. This has not been independently confirmed and is not used in the elimination curve.
100 × 2−time / half-life. Time zero is a reference level, not the moment of administration. Absorption, repeated dosing, metabolites and clinical effects are not modeled. Five half-lives leaves 3.125%, not zero. This curve cannot determine a dosing interval.
What to expect
Study outcomes
Scope of evidence
Clinical liver benefits, human pharmacokinetics and treatment safety were not established.1
Community poll 4 topics · Pep-Pedia snapshot
Voluntary, unverified reports. These percentages do not measure effectiveness or safety.
Experience
Number of responses to this question: not disclosed.
Duration of use
Number of responses to this question: not disclosed.
Age range
Number of responses to this question: not disclosed.
Gender
Number of responses to this question: not disclosed.
Source & limitations
The source displays “5 responses” for this profile. This is not a confirmed participant count or a denominator for individual questions.
- Voluntary self-reports from Pep-Pedia visitors; identity, treatment, outcomes and timing are unverified. These data are not efficacy or safety estimates.
- The source displays a profile-wide response label, not a confirmed unique participant count. It stays unchanged across questions. Question-specific denominators and absolute option counts are not exposed.
- Only the top five categories are displayed for some questions. Extra categories are retained as an undisplayed-category count; their labels and percentages are unavailable.
- Displayed percentages are rounded. They may not total 100%, especially where categories are hidden.
- This is a dated snapshot, not a live survey or current recommendation.
Protocols
Doses & schedules
Compare purpose, amount, route, frequency, and duration.
Source corrections
Source labels are hypotheses; natural amino acids and absent adverse-event reporting do not prove safety.
No verified human protocol or quantified community report included.
Study and label doses retain their study context. Reference reports are unvalidated practices, not personal treatment instructions. Ranges remain ranges; escalation stages are labeled.
Reported use periods and breaks. These do not establish a safe cycle or prove that breaks prevent tolerance.
Injectable
- Use period
- 2 weeks (rat oral protocol). Community injectable cycles run 10-20 days without published validation.
- Break
- Khavinson protocol framework references quarterly cycles; no published evidence-based interval.
Reported timing
Partial oral bioavailability documented in rats (PMID 16075683); no measured Cmax / Tmax / half-life published.
Oral
- Use period
- 2 weeks (rat) or per product label
- Break
- Per product label
Reported timing
Partial oral bioavailability in rats (PMID 16075683); no human PK published
Side effects & safety
Clinical gap
Cell-culture chromatin changes do not establish liver regeneration or clinical anti-aging safety.
1Biological meaning
Chromatin decondensation is a laboratory readout; its benefits and risks during systemic exposure remain unresolved.
1Unknown safety/exposure
No structured human safety/PK; oral absorption unquantified. Pregnancy, childhood and organ impairment unstudied.
Identity and stop symptoms
KEDA differs from Testagen KEDG; allergy, neurological effects or persistent local/systemic symptoms warrant review.
Not a complete safety screen. Discuss health decisions with a qualified clinician.
Combinations & interactions
9 entriesCheck cautions and reported pairings. A compatibility claim does not establish that a combination is safe.
Testagen
Caution reportedSequence/product confusion.12
Reference report · Pep-Pedia label: Use CautionOpioids/enkephalinase inhibitors
Caution reportedIn-vitro mechanism concern.12
Reference report · Evidence context: Monitor combinationCancer chemotherapy
Avoidance reportedUncertain chromatin-treatment interaction.12
Reference report · Pep-Pedia label: Avoid CombinationEpitalon
Unverified pairingShared experimental chromatin effects, not clinical synergy.12
Reference report · Pep-Pedia label: SynergisticVilon
Unverified pairingUntested pairing.12
Reference report · Pep-Pedia label: CompatibleCortagen
Unverified pairingUntested pairing.12
Reference report · Pep-Pedia label: CompatibleImmunosuppressants
Unverified pairingNo interaction data.12
Reference report · Evidence context: UnknownHepatotoxic medicines
Unverified pairingNot proven protective.12
Reference report · Evidence context: UnknownOther peptides and medicines
Not establishedA controlled interaction assessment for this exact compound and formulation was not identified in the sources checked. Absence of interaction data is not evidence of compatibility.2
Research contextNo matching interactions. Try another name or filter.
Reconstitution
A product-specific preparation or sterility protocol has not been verified.2
Dilution
A concentration calculation cannot establish a suitable diluent, compatibility, storage interval, or sterility. No universal bacteriostatic-water volume is assigned.2
Reference preparation details
Reported handling information, not a validated formulation or instruction to prepare an injectable product.
Injectable
Pep-Pedia labels its preparation and storage guidance as conventions from related short peptides, not human PK data.
- Solvents mentioned
- 0.9% sterile sodium chloride / Bacteriostatic water
- Reported parameters
- Dry and prepared material: reported 2–8°C. · Reported prepared-solution interval: 7–10 days. · Community concentration example: 10 mg in 1–2 mL.
The source describes gentle mixing and avoiding vigorous shaking.
Oral
The source describes Russian supplement capsules and no established human oral dose.
- Form
- Source describes a prepared product
- Reported parameters
- Storage and shelf life are product-label dependent.
Appearance & documentation
Appearance and a purity certificate cannot establish sterility, identity, or suitability for injection.
Reported appearanceWhite lyophilized powderReported appearanceSealed vial with batch and expiryReported appearanceClear reconstituted solutionReported appearanceRefrigerated cold chainReported variationVerify sequence is KEDA, not KEDGReported variationResearch-grade onlyReported concernCloudy, yellow, or particulate solution
12Available forms
No verified packaging examples included.
Packaging examples, not a market survey. Approved and research products are not interchangeable.
Storage after mixing
Reconstituted research vials
Pep-Pedia reports these handling limits after mixing. They are not validated stability or sterility limits for your vial.
Full storage notes from Pep-Pedia
12Lyophilized: 2-8°C. Reconstituted: 2-8°C, use within 7-10 days.
Per product label
Storage depends on the formulation, diluent, container, and handling. Follow the specific product label or pharmacist’s instructions.
Research findings
PreclinicalSource context
Source labels are hypotheses; natural amino acids and absent adverse-event reporting do not prove safety.
Compound identity & other names
Livagen is an experimental short peptide studied in chromatin and cell-aging models. Human donor cells in a laboratory are not a human treatment trial, and liver-regeneration claims remain unverified clinically.
Other names: Lys-Glu-Asp-Ala · KEDA
Investigational; this profile does not establish an approved use.
How it may work
Chromatin-decondensation/ribosomal-gene and enkephalinase findings; physiological relevance and receptor targets remain uncertain.12
Older-donor lymphocyte cultures
The study examined chromatin changes in cultured lymphocytes from adults aged 75–88. Participants were donors; the peptide was not tested as a clinical anti-aging treatment.
1Research areas and evidence gaps
Chromatin and cell aging. Experimental research; clinical benefit is not established.1
- Clinical liver benefits, human pharmacokinetics and treatment safety were not established.
- The evidence does not validate the identity, purity or handling of a separately sourced research product.
Community reports Unvalidated
Pep-Pedia reports use in the research-peptide community. These reports are not clinical evidence.2
No numeric human-use schedule was captured in the inspected Pep-Pedia protocol section.
Community protocol tables are unvalidated descriptions, not treatment instructions.
Search coverage and review status
Additional primary or regulatory sources were checked. No further 2025–2026 exact-compound clinical outcome study was identified in this targeted search; this is not evidence that none exists.
- Checked
- 2026-10-12
- Search
- Livagen peptide study
- Catalog
- Pep-Pedia ↗ · 8 listed references retained
- Targeted search, not a systematic or exhaustive review.
- Retained bibliography entries marked Bibliography only have not been independently verified.
- Distinct URLs may refer to the same publication; component and formulation boundaries remain important.
AI-prepared summaries. Independent medical editorial review is pending.
References
Original sources and review status. Open a reference to read its summary.
1Anti-aging peptide bioregulators induce reactivation of chromatinAbstract checked
AI-PREPARED SUMMARY
Livagen, Epitalon and Vilon were investigated in cultured lymphocytes from older donors.
Older-donor lymphocyte cultures
The study examined chromatin changes in cultured lymphocytes from adults aged 75–88. Participants were donors; the peptide was not tested as a clinical anti-aging treatment.
Additional research · Checked 2026-10-12
2Pep-Pedia: LivagenCommunity source checked
AI-PREPARED SUMMARY
Secondary community overview checked on 12 October 2026. Its practice tables and efficacy claims are not independently validated clinical guidance.
3Khavinson VKh, Lezhava TA, Monaselidze JG, Dzhokhadze TA, Dvalishvili NA, Bablishvili NK, Ryadnova IYu (2002). Effects of Livagen peptide on chromatin activation in lymphocytes from old people. Bulletin of Experimental Biology and Medicine, 134(4), 389-392.Pep-Pedia report · Primary source not checked
AI-PREPARED SUMMARY
Pep-Pedia reports: Elderly-donor lymphocytes showed altered chromatin packing and ribosomal-gene activity; clinical liver or aging benefits were not measured.
Reported population / model
Human
Reported study details
Ex vivo lymphocytes · Elderly donors · Khavinson-Lezhava
Reported by Pep-Pedia; the linked publication, design, doses and result have not been independently verified here.
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
4Kost NV, Sokolov OYu, Gabaeva MV, Zolotarev YuA, Malinin VV, Khavinson VKh (2003). Effect of new peptide bioregulators livagen and epitalon on enkephalin-degrading enzymes in human serum. Izvestiya Akademii Nauk, Seriya Biologicheskaya, (4), 427-429.Pep-Pedia report · Primary source not checked
AI-PREPARED SUMMARY
Pep-Pedia reports: Livagen inhibited serum enkephalin-degrading enzymes around 20 μM without direct opioid-receptor binding; relevant human exposure is unknown.
Reported population / model
In vitro
Reported study details
Human serum · Enkephalinase assay
Reported by Pep-Pedia; the linked publication, design, doses and result have not been independently verified here.
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
5Timofeeva NM, Khavinson VKh, Malinin VV, Nikitina AA, Egorova VV (2005). Effect of peptide Livagen on activity of digestive enzymes in gastrointestinal tract and non-digestive organs in rats of different ages. Advances in Gerontology, 16, 92-96.Pep-Pedia report · Primary source not checked
AI-PREPARED SUMMARY
Pep-Pedia reports: Aged rats had digestive-enzyme activity closer to young controls after oral exposure; resistance to breakdown alone does not quantify bioavailability.
Reported population / model
Rat
Reported study details
Oral gavage · 2 weeks · Age-stratified
Reported by Pep-Pedia; the linked publication, design, doses and result have not been independently verified here.
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
6Brodsky VI, Khavinson VKh, Zolotarev YuA, et al. (2001). Rhythm of protein synthesis in cultures of hepatocytes from rats of different ages. Norm and effect of the peptide livagen. Izvestiya Akademii Nauk, Seriya Biologicheskaya, (5), 517-521.Pep-Pedia report · Primary source not checked
AI-PREPARED SUMMARY
Pep-Pedia reports: Rat hepatocyte cultures showed greater protein synthesis, especially in older cells; Epitalon did not show that response in the comparison.
Reported population / model
Rat
Reported study details
Cultured hepatocytes · Age-stratified
Reported by Pep-Pedia; the linked publication, design, doses and result have not been independently verified here.
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
7Lezhava T, Jokhadze T (2007). Activation of pericentromeric and telomeric heterochromatin in cultured lymphocytes from old individuals. Annals of the New York Academy of Sciences, 1100, 387-399.Pep-Pedia report · Primary source not checked
AI-PREPARED SUMMARY
Pep-Pedia reports: Old-donor lymphocytes showed chromatin changes with Livagen and related peptides; the work came from a connected research network.
Reported population / model
Human
Reported study details
Ex vivo lymphocytes · Lezhava-Jokhadze
Reported by Pep-Pedia; the linked publication, design, doses and result have not been independently verified here.
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
8Kuznik BI, Hasanova NB, Ryzhak GA, Meshcheryakova IE, Khavinson VK (2020). The influence of polypeptide liver complex and tetrapeptide KEDA on organism physiological function in norm and age-related pathology. Advances in Gerontology, 33(1), 159-164.Pep-Pedia report · Primary source not checked
AI-PREPARED SUMMARY
Pep-Pedia reports: The review describes rodent hepatitis/cirrhosis findings for a liver extract and KEDA; neither is established as effective human therapy by these models.
Reported population / model
Review
Reported study details
Rat hepatitis / cirrhosis models
Reported by Pep-Pedia; the linked publication, design, doses and result have not been independently verified here.
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
9Khavinson VKh, Lezhava TA, Monaselidze JG, Dzhokhadze TA, Dvalishvili NA, Bablishvili NK, Ryadnova IYu (2002). Effects of Livagen peptide on chromatin activation in lymphocytes from old people. Bulletin of Experimental Biology and Medicine, 134(4), 389-392.Linked reference · Not independently reviewed
REFERENCE NOTE
Reference retained from Pep-Pedia’s bibliography. The original source and the website’s description have not been independently verified; the listed title may not match the linked record.
Pep-Pedia bibliography · Checked 2026-10-12
10Lezhava T, Jokhadze T (2007). Activation of pericentromeric and telomeric heterochromatin in cultured lymphocytes from old individuals. Annals of the New York Academy of Sciences, 1100, 387-399.Linked reference · Not independently reviewed
REFERENCE NOTE
Reference retained from Pep-Pedia’s bibliography. The original source and the website’s description have not been independently verified; the listed title may not match the linked record.
Pep-Pedia bibliography · Checked 2026-10-12
11Pep-Pedia: Livagen — reported pharmacokineticsReference estimate; not independently verified human PKCommunity source checked
AI-PREPARED SUMMARY
Lists a half-life of 30 min and a peak time of 3 min. Stated attribution: Timofeeva et al. 2005 Adv Gerontol (PMID 16075683). This value is reported by a secondary reference. The stated attribution has not been independently verified as a route- and formulation-matched human PK measurement. Five half-lives is not complete clearance, and the source’s “cleared” value is not used as a measured endpoint.
Secondary reference page checked; the underlying quantitative claim is not independently confirmed. · Checked 2026-10-12
12Pep-Pedia: Livagen — route-specific referenceReference page checked; underlying claims require separate verification.Community source checked
AI-PREPARED SUMMARY
Source page checked across available routes. Protocols, cycles, storage, mechanisms and pairing claims are secondary reports; checking the page does not independently validate those claims. Original concise summaries are used here.
Content coverage audit · Checked 2026-10-12